vs
Side-by-side financial comparison of ALNYLAM PHARMACEUTICALS, INC. (ALNY) and AXIS CAPITAL HOLDINGS LTD (AXS). Click either name above to swap in a different company.
AXIS CAPITAL HOLDINGS LTD is the larger business by last-quarter revenue ($1.6B vs $1.2B, roughly 1.4× ALNYLAM PHARMACEUTICALS, INC.). ALNYLAM PHARMACEUTICALS, INC. runs the higher net margin — 17.6% vs 15.5%, a 2.1% gap on every dollar of revenue. On growth, ALNYLAM PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (96.4% vs 8.0%). Over the past eight quarters, ALNYLAM PHARMACEUTICALS, INC.'s revenue compounded faster (33.0% CAGR vs 6.4%).
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.
AXIS Capital Holdings Limited is the holding company for AXIS group of companies. It offers various risk transfer products and services through subsidiaries and branch networks in Bermuda, the United States, Canada, Europe and Singapore. The company offers insurance services including property, professional lines, terrorism, marine, energy, environmental and other insurance. The reinsurance services include property, professional lines, credit and bond, and others.
ALNY vs AXS — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.2B | $1.6B |
| Net Profit | $206.0M | $254.8M |
| Gross Margin | 82.2% | — |
| Operating Margin | 23.0% | 15.6% |
| Net Margin | 17.6% | 15.5% |
| Revenue YoY | 96.4% | 8.0% |
| Net Profit YoY | — | 31.3% |
| EPS (diluted) | $1.51 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.2B | $1.6B | ||
| Q4 25 | $1.1B | $1.7B | ||
| Q3 25 | $1.2B | $1.7B | ||
| Q2 25 | $773.7M | $1.6B | ||
| Q1 25 | $594.2M | $1.5B | ||
| Q4 24 | $593.2M | $1.5B | ||
| Q3 24 | $500.9M | $1.6B | ||
| Q2 24 | $659.8M | $1.5B |
| Q1 26 | $206.0M | $254.8M | ||
| Q4 25 | $186.4M | $289.6M | ||
| Q3 25 | $251.1M | $301.9M | ||
| Q2 25 | $-66.3M | $223.4M | ||
| Q1 25 | $-57.5M | $194.1M | ||
| Q4 24 | $-83.8M | $293.6M | ||
| Q3 24 | $-111.6M | $180.7M | ||
| Q2 24 | $-16.9M | $212.0M |
| Q1 26 | 82.2% | — | ||
| Q4 25 | 75.6% | — | ||
| Q3 25 | 84.2% | — | ||
| Q2 25 | 81.6% | — | ||
| Q1 25 | 88.2% | — | ||
| Q4 24 | 82.7% | — | ||
| Q3 24 | 83.6% | — | ||
| Q2 24 | 89.8% | — |
| Q1 26 | 23.0% | 15.6% | ||
| Q4 25 | 12.0% | 19.0% | ||
| Q3 25 | 29.5% | 22.1% | ||
| Q2 25 | -2.1% | 17.2% | ||
| Q1 25 | 3.0% | 15.5% | ||
| Q4 24 | -17.7% | 18.6% | ||
| Q3 24 | -15.4% | 14.2% | ||
| Q2 24 | 7.4% | 17.4% |
| Q1 26 | 17.6% | 15.5% | ||
| Q4 25 | 17.0% | 16.7% | ||
| Q3 25 | 20.1% | 18.0% | ||
| Q2 25 | -8.6% | 13.7% | ||
| Q1 25 | -9.7% | 12.8% | ||
| Q4 24 | -14.1% | 20.0% | ||
| Q3 24 | -22.3% | 11.2% | ||
| Q2 24 | -2.6% | 14.6% |
| Q1 26 | $1.51 | — | ||
| Q4 25 | $1.44 | $3.63 | ||
| Q3 25 | $1.84 | $3.74 | ||
| Q2 25 | $-0.51 | $2.72 | ||
| Q1 25 | $-0.44 | $2.26 | ||
| Q4 24 | $-0.66 | $3.38 | ||
| Q3 24 | $-0.87 | $2.04 | ||
| Q2 24 | $-0.13 | $2.40 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.7B | $862.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.1B | $6.4B |
| Total Assets | $5.1B | $35.6B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $1.7B | $862.5M | ||
| Q4 25 | $1.7B | $820.3M | ||
| Q3 25 | $1.5B | $825.9M | ||
| Q2 25 | $1.1B | $852.1M | ||
| Q1 25 | $1.0B | $2.8B | ||
| Q4 24 | $966.4M | $2.1B | ||
| Q3 24 | $1.1B | $981.0M | ||
| Q2 24 | $968.5M | $1.1B |
| Q1 26 | $1.1B | $6.4B | ||
| Q4 25 | $789.2M | $6.4B | ||
| Q3 25 | $233.9M | $6.4B | ||
| Q2 25 | $250.6M | $6.2B | ||
| Q1 25 | $115.4M | $5.9B | ||
| Q4 24 | $67.1M | $6.1B | ||
| Q3 24 | $32.4M | $6.1B | ||
| Q2 24 | $-3.1M | $5.7B |
| Q1 26 | $5.1B | $35.6B | ||
| Q4 25 | $5.0B | $34.5B | ||
| Q3 25 | $4.9B | $34.3B | ||
| Q2 25 | $4.6B | $34.2B | ||
| Q1 25 | $4.2B | $33.2B | ||
| Q4 24 | $4.2B | $32.5B | ||
| Q3 24 | $4.2B | $32.7B | ||
| Q2 24 | $4.0B | $32.1B |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ALNY
| AMVUTTRA | $889.9M | 76% |
| GIVLAARI | $74.4M | 6% |
| OXLUMO | $51.3M | 4% |
| Royalty revenue | $49.0M | 4% |
| Regeneron Pharmaceuticals | $46.3M | 4% |
| Roche | $35.6M | 3% |
| ONPATTRO | $20.5M | 2% |
AXS
Segment breakdown not available.
